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Abstract: Psychotic symptoms emerging in the context of neurodegeneration as a consequence
of Alzheimer’s disease was recognized and documented by Alois Alzheimer himself in his
description of the first reported case of the disease. Over a quarter of a century ago, in the context
of attempting to develop prognostic markers of disease progression, psychosis was identified as
an independent predictor of a more-rapid cognitive decline. This finding has been subsequently
well replicated, rendering psychotic symptoms an important area of exploration in clinical history taking – above and beyond treatment necessity – as their presence has prognostic significance. Further, there is now a rapidly accreting body of research that suggests that psychosis
in Alzheimer’s disease (AD+P) is a heritable disease subtype that enjoys neuropathological
specificity and localization. There is now hope that the elucidation of the neurobiology of the
syndrome will pave the way to translational research eventuating in new treatments. To date,
however, the primary treatments employed in alleviating the suffering caused by AD+P are the
atypical antipsychotics. These agents are approved by the US Food and Drug Administration for
the treatment of schizophrenia, but they have only marginal efficacy in treating AD+P and are
associated with troubling levels of morbidity and mortality. For clinical approaches to AD+P
to be optimized, this syndrome must be disentangled from other primary psychotic disorders,
and recent scientific advances must be translated into disease-specific therapeutic interventions.
Here we provide a review of atypical antipsychotic efficacy in AD+P, followed by an overview
of critical neurobiological observations that point towards a frontal, tau-mediated model of
disease, and we suggest a new preclinical animal model for future translational research.
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There is urgency to the problem of the need for efficacious drug treatment in the
management of Alzheimer’s disease with psychosis (AD+P). AD+P has grave consequence, particularly for caregivers, as it is associated with physical aggression, and
caregivers are most often the victims.1–3 Violent behavior that is directed towards
caregivers is disruptive of care at the very least, but can also be dangerous for those
charged with providing a safe environment for those suffering with disease. Not only
is aggressive behavior inherently troublesome for families, but perhaps in part because
of the difficulty of managing these behaviors, the rates of institutionalization are much
higher in AD patients who have exhibited violent behavior.4,5 Notably, in one study
of participants with elevated levels of physical aggression, 80% had delusions.6 This
suggests that psychosis at least aggravates the clinical course of AD, and creates
profound caregiver stress that compounds the difficulty of taking care of a loved one
with the cognitive impairment that is a defining feature of the illness.
Unfortunately, the current treatment approaches to AD+P, relying mostly on
agents approved for the treatment of schizophrenia, have been largely disappointing.
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The efficacy of the atypical antipsychotics in the treatment
of behavioral and psychological symptoms of dementia –
derived from randomized placebo-controlled trials – has
been parsed many ways, owing in part to the broad range of
rating scales employed as outcome measures and the spectrum of neurobehavioral syndromes associated with AD.
Indeed, trials that have enrolled over 5,000 patients to date
have included a number of different psychometric scales
of behavioral impairment, including the Neuropsychiatric
Inventory (NPI); the Brief Psychiatric Rating Scale (BPRS);
the Cohen-Mansfield Agitation Inventory; the Clinical Global
Impression of Change; the Clinical Global Impression of
Severity; and the Behavioral Pathology in Alzheimer’s
Disease (BEHAVE-AD). Evaluating the efficacy of currently
available treatments in AD+P is challenging, as the only
available data comprises subscales distilled from comprehensive agitation inventories.
The most recent and most comprehensive meta-analysis
to date of randomized placebo-controlled trials in the treatment of the behavioral and psychological symptoms of
dementia7 suggests a consistent superiority of atypical agents
(aripiprazole, quetiapine, olanzapine, risperidone) over
placebo as measured with the aforementioned behavioral
rating scales. In fact, when atypical agents are amalgamated
and their efficacy data is compared with placebo, the most
recent meta-analysis reveals that antipsychotics demonstrate
a convincing superiority over placebo in the treatment of
behavioral disturbances. Calculated mean differences and
95% confidence intervals on behavioral rating scales support this contention: BPRS, -1.58 (-2.52 to -0.65); CohenMansfield Agitation Inventory, -1.84 (-3.01 to -0.61);
NPI, -2.81 (-4.35 to -1.28); Clinical Global Impression of
Change, -0.32 (-0.44 to -0.20); Clinical Global Impression
of Severity, -0.19 (-0.3 to -0.09). These data, especially in
light of the BPRS differences, could be taken as evidence
that atypical antipsychotics are efficacious in the treatment
of AD+P.
A careful look at these studies, however, suggests the
ironic truth that amongst therapies for behavioral disturbances in AD, the atypical antipsychotics are inconsistent
at best in the treatment of psychosis. Positive results from
the above referenced meta-analytic data on BPRS total score
outcomes do not necessarily reflect improvement in psychosis. The BPRS, (Overall and Gorham 1962, Psychological
Report)8 an inventory of psychopathology that has been
extensively utilized in the evaluation of outcomes in schizophrenia and other psychotic illnesses, is a remarkably broad
18-item scale.9 Only a few items could be interpreted with any
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relevance in AD+P: hostility, suspiciousness, hallucinatory
behavior, and perhaps unusual thought content and uncooperativeness. Although not included in the most recent
meta-analysis, data on psychosis can be extracted from the
majority of placebo-controlled clinical trials of antipsychotics
in dementia populations by looking at psychosis subscores
derived from the NPI, the BEHAVE-AD, and the BPRS
(Table 1). Olanzapine has been evaluated in comparison
with placebo over 6–36 weeks in nursing home patients
and outpatients.10–12 In the first study, olanzapine at a dose
of 5 mg and 10 mg, but not 15 mg, was superior to placebo
on the psychosis subscale total score derived from the nursing home version of the NPI, the NPI-NH (Table 1).10 In a
second study of 1.0 mg, 2.5 mg, 5.0 mg, and 7.5 mg doses
of olanzapine, only the 7.5 mg dose was superior to placebo
as measured by the NPI-NH psychosis subscale.11 In the
Clinical Antipsychotics Trials of Intervention EffectivenessAlzheimer’s Disease (CATIE-AD) study, an outpatient
study comparing flexible doses of atypical antipsychotics
(olanzapine, quetiapine, risperidone) to placebo, olanzapine
at a mean dose of 5.5 mg was not superior to placebo on the
psychosis factor of the BPRS.12 Two 10-week randomized
placebo-controlled trials have investigated aripiprazole in
the treatment of AD+P.13,14 In the first study, an outpatient
study employing a flexible dose, aripiprazole at a mean dose
of 10 mg demonstrated superiority to placebo on the BPRS
psychosis subscale but not on the NPI psychosis subscale.13
In a nursing home study, comparing aripiprazole at doses of
2 mg, 5 mg, and 10 mg, only 10 mg was superior to placebo
on the NPI-NH psychosis subscale.14 Two studies, of 6 weeks
and 36 weeks duration in nursing facilities and outpatient
populations, respectively, have evaluated the efficacy of
quetiapine in comparison with placebo for the treatment of
AD+P.12,15 No evidence of efficacy in treating psychosis was
generated for quetiapine from either study on the basis of the
BPRS psychosis subscales. Prior to CATIE-AD, there were
four randomized placebo-controlled trials of risperidone in
AD+P, ranging from 8–36 weeks in both the nursing home
residents and outpatients.16–19 A meta-analysis of these four
studies revealed that risperidone was superior to placebo on
the BEHAVE-AD psychosis subscale, with an effect size of
0.154 (95% confidence interval 0.038–0.269), suggesting
only a modest effect of drug treatment.20 Data from CATIE-AD also evidenced a benefit of risperidone over placebo
on the BPRS psychosis factor, the only agent to beat placebo
on this measure.12 The data on atypical antipsychotics, while
inconsistent, do suggest some utility for most agents, with
some superiority for risperidone; however, the magnitudes of
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Table 1 Randomized placebo-controlled trials of atypical antipsychotics in the treatment of Alzheimer’s disease with psychosis
Study
Street et al

10

De Deyn et al11

De Deyn et al13

Mintzer et al14
Tariot et al15
Katz et al20
Katz et al16
De Deyn et al17
Brodaty et al18
Mintzer et al19
Sultzer et al12

Agent

N

Outcome measure

Outcome

Olanzapine 5 mg, 10 mg
versus placebo
Olanzapine 1.0 mg, 2.5 mg,
5.0 mg, 7.5 mg versus
placebo
Aripiprazole versus placebo

206

NPI psychosis subscale

652

NPI psychosis subscale

5 mg and 10 mg superior to placebo,
15 mg not superior to placebo
7.5 mg superior to placebo; 1.0 mg,
2.5 mg, 5.0 mg not superior to placebo

208

BPRS psychosis subscale;
NPI psychosis subscale

Aripiprazole 2 mg, 5 mg,
10 mg versus placebo
Quetiapine versus
haloperidol versus placebo
Risperidone vs placebo

487

NPI psychosis subscale

284

BPRS thought disturbance

941

Meta-analysis of BEHAVEAD psychosis subscale

Olanzapine versus
quetiapine versus
risperidone versus placebo

421

BPRS psychosis subscale;
hostile suspiciousness factor

Mean dose 10 mg superior to placebo
on BPRS psychosis subscale but not NPI
psychosis subscale
10 mg superior to placebo, 2 mg, 5 mg
not superior to placebo
Mean dose 96.9 mg quetiapine, 1.9 mg
haloperidol, neither superior to placebo
Mean dose 1.09 mg risperidone
superior to placebo, effect size 0.154
(range 95% CI, 0.038–0.269)

Mean dose olanzapine 5.5 mg superior
to placebo on hostile suspiciousness
but not psychosis subscale; 56.5 mg
quetiapine not superior to placebo;
risperidone 1 mg superior to placebo
on both psychosis and hostile
suspiciousness subscale

Abbreviations: BEHAVE-AD, Behavioral Pathology in Alzheimer’s Disease scale; BPRS, Brief Psychiatric Rating Scale; N, number; NPI, Neuropsychiatric Inventory; CI,
confidence interval.

treatment effects are not robust, and highly efficacious agents
are desperately needed. One solution to this problem is to
develop novel treatments based on the emerging neurobiology of AD+P, rather than relying on existing treatments for
other psychotic conditions.

Phenomenology in AD+P:
theoretical considerations
Psychotic symptoms in AD comprise delusions, with a
reported prevalence of between 30%–40%, 21–24 and, to
a smaller extent, hallucinations, with a prevalence of
5%–20%.21,23,25–27 The heritability of AD+P has been firmly
established28 and is estimated to be between 30%–60%.29 The
persistence of untreated psychosis over time in Alzheimer’s
disease in individual patients has not been firmly established, but available evidence suggests that approximately
40%–50% of psychotic individuals will continue to manifest psychotic symptoms after 1 year. 30 Rather than the
bizarre delusions and complex network of unsubstantiated
belief systems commonly seen in schizophrenia typified
by logical impossibility and experiences alien to “ordinary
life situations,”31 the delusions in AD+P generally involve
rather narrow elaborations and distortions of actual experience. The delusions of AD have been largely reconciled
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into two categories,32,33 delusions of persecution (eg, theft,
harm, jealousy, abandonment)2,34–36 and delusions of misidentification (eg, phantom boarder, television images are
animate, Capgras syndrome, house is not one’s home),2,35–38
the latter having once been conceptualized as representing
perceptual abnormalities, but actually representing ideational
fixations.32,39,40 A category of “autobiographical delusions,”32
for instance that a dead relative is still alive, has also been
suggested,41 but these may be regarded as an extension of
the misidentification domain.
A few theoretical models have been developed to explain
the common emergence of psychosis in AD – particularly
focused on delusions – in those otherwise not afflicted with
mental illness. Carefully reviewed by Reeves et al32 the earliest of these ratiocinations suggested that psychosis results
from a “logical attempt to understand the environment” in
the context of degraded cognitive integrity.42 For instance,
the common delusions in AD – theft, jealousy, misidentification, abandonment, phantom boarder, television images are
animate21,43,44 – are possible narrative confabulations that fill
in the gaps or normalize the experiences of those confronted
with a history they have become unmoored from, and who
rely on a gradually eroding apparatus for discriminating
object from representation. The most intuitive support for
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this model comes from the most prevalent delusion in AD,
that people are hiding or stealing things,45–47 a potential
confabulation that is entirely consistent with the primary
cognitive deficit in AD, accelerated forgetting. Alternatively,
some have suggested that brain disease results in “release
symptomatology”48 or that cognitive deficits germinate
delusional ideas as a consequence of a “lack of corrective
judgment” from other cortical structures.49 These conceptualizations, while interesting, are broad and speculative and do
not really generate any testable scientific predictions. More
recent work has been focused on concrete neurobiological
correlates of psychotic AD, and from that a glimpse of disease
pathophysiology has begun to emerge.

Cognitive course and mortality
in AD+P: evidence for a distinct
syndrome?
The earliest specific reference to the problem of psychosis
in the modern literature on Alzheimer’s disease emerges in
a Russian neuropsychiatric journal in 1964.50 It was another
20 years before critical observations were made that contributed to a reconceptualization of psychotic phenomena as
expressions of a unique pathophysiological syndrome rather
than a mere behavioral nuisance. In the context of searching
for clinical signs that would predict the velocity of decline
in AD, psychosis – in addition to myoclonus and extrapyramidal signs – was found to be an early marker heralding
a hastened deterioration.51,52 This observation was quickly
replicated in several studies reinforcing the prognostic value
of psychosis in relationship to decline.53,54 Studies focused on
the exploration of risk factors for psychotic symptoms in AD
have also consistently identified a greater burden of cognitive impairment as an independent risk factor for psychosis,
with acceleration of decline emerging prior to the onset of
psychosis.24,46,55,56
The features of accelerated cognitive impairment in
AD+P suggest some degree of frontal localization. In one
study of AD+P and Alzheimer’s disease without psychosis
(AD-P) that compared subjects of similar duration of illness, age, and education, AD+P subjects evidenced more
impairment on tasks of frontal-lobe function, including the
Wisconsin Card Sorting Test and the similarities subtest
of the Wechsler Adult Intelligence Scale.57 Recent studies
suggest that working memory performance, a test of frontal
function depending largely on the dorsolateral prefrontal
cortex, enjoys a unique association with psychosis in AD.
Early evidence for this emerged from an epidemiological
study of AD+P risk factors, wherein performance on the
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digit span, a task of working memory, was observed to be a
robust predictor of future psychosis in AD.24 Impressively, a
one-standard-deviation improvement in this task reduced the
risk of developing hallucinations or delusions by two thirds.
In our own study of cognition in AD+P, we evaluated AD
and performed stepwise regression of cognitive domains in
order to determine whether any cognitive domains (memory,
executive function, language) predicted psychosis. We found
that of the wide spectrum of domains of cognition interrogated in the analysis, only working memory interacted with
psychosis.58
In order to replicate the finding and to determine whether
working memory, beyond its mere association with the state
of psychosis, might track uniquely with the accelerated
decline in AD+P, we performed an analysis of cognitive
data from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) study database. The ADNI database includes longitudinal cognitive data on subjects some of whom destined
to become psychotic, as evidenced by psychometric ratings,
over the course of the study. We hypothesized that digit-span
performance, amongst available cognitive metrics, would
decline more rapidly over time as a marker of the accelerated
decline of AD+P. Results of the analysis demonstrated that
digit-span performance is one of only two cognitive measures
that decline more rapidly in AD+P when compared with
AD-P.59 It is not clear how impairment in working memory
is etiologically related to AD+P. One possibility is that it is
merely a byproduct of frontal degeneration, and not directly
etiologically related; another is that accelerated frontal
degeneration engenders working memory deficits, and that
failures in working memory impair successful environmental
surveillance in AD, culminating in misinterpretations and
psychosis.
Evidence of a more aggressive cognitive phenotype as a
marker of virulence would predict an acceleration of overall
decline and decreased survival rates in those with AD+P. It is
puzzling, given the established relationship between rate of
cognitive decline and mortality in AD,60,61 that most,53,60–65
but not all,66 early studies did not find an increased mortality
rate in AD+P. More recent studies, with larger sample sizes
and an enhanced follow-up with a more powerful statistical
approach (Cox proportional hazard regression analysis) have
consistently observed the predictive value of psychosis in
AD survival.67–70
A parsimonious hypothesis that explains the accelerated
cognitive deterioration with some specificity and the early
demise of patients with AD+P is that psychosis is a behavioral
expression of a more-rapid neurodegenerative process that
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may be regional. If so, what regions are implicated? What
are the neurochemical and neuropathological hallmarks
of this distinct AD syndrome? Can answers to these questions point the way forward in developing new anti-AD+P
treatments?

Imaging correlates in AD+P: a
predominance of frontal localization
In the search for cerebral localization of deficit patterns in
AD+P, investigators have, with varying levels of success
related to sample sizes and heterogeneous subject composition, availed themselves of structural and functional neuroimaging. The literature on imaging in AD+P has been recently
reviewed and thoughtfully organized by Murray et al71 who
separated the studies by methodological approach, including
computed tomography, magnetic resonance imaging (MRI),
single-photon emission computed tomography, and [18F]fluorodeoxyglucose position emission tomography (PET)
studies. As the authors highlight, with some variability and
inconsistency, the preponderance of imaging evidence across
methodologies implicate the frontal lobes.71 A computed
tomography study investigating regional brain atrophy in
AD+P found that subjects with delusions demonstrated frontal and temporal patterns of asymmetric atrophy, compared
with AD-P subjects.72 MRI studies of AD+P have generally
implicated the frontal cortex, with both orbitofrontal and
medial frontal involvement.73,74 PET studies – with only
one exception75 – have consistently shown frontal hypometabolism in AD+P relative to AD-P.76–80 In an analysis of a
large, well-controlled sample drawn from the ADNI database,
we observed a specific relationship between orbitofrontal
hypometabolism and AD+P.59

Neurotransmission in AD+P
An early theory promulgated in an effort to explain the
prevalence of psychosis in AD suggested that a preservation
of dopaminergic tone in the context of early cholinergic deficits may result in a relative “hyperdopaminergic” state, with
resultant psychosis.81 However evidence for a relative excess
of dopaminergic tone has been limited. An early postmortem
study of neurotransmission in psychotic AD did not identify
any abnormalities in markers of dopamine signaling.82 One
small postmortem study suggested a selective increase in
D3 receptor availability.83 Further, using [11C]-raclopride
PET, a modest increase in tracer binding in the striatum was
observed in a cohort of delusional patients, suggesting some
increase in D3 availability.84 Yet, a recent comprehensive
postmortem study of monoaminergic correlates of behavioral
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symptoms in AD did not observe any relationship between
alterations in dopamine or dopamine metabolite concentrations in nine behaviorally and neurochemically relevant brain
regions and psychotic symptoms in AD.85
Perturbations in serotonergic systems have been reported
in postmortem studies of psychotic AD. A reduction of
serotonin (5-HT) has been reported in several studies across
several brain regions,82,86 as have altered 5-HT6 receptor function87 and a reduction in cell counts in the dorsal
raphe nucleus.88 In a recent study, a significant reduction in
serotonergic tone comprising lower 5-hydroxyindoleacetic
acid concentrations in the hippocampus and lower 5-HT
concentrations in the superior temporal gyrus and cerebral
cortex, correlated with dementia severity.85 It may be that the
association observed in previous studies between psychosis
in AD and reduced 5-HT may be related to regional disease
severity in psychotic AD, and not an independent risk factor
for the emergence of the syndrome.
Although currently available agents have not achieved
satisfying rates of success in treating AD+P, continued
exploration of perturbations in neurotransmitter systems
in AD+P, together with the advent of more-sophisticated
supportive therapeutics, may prove helpful in treating this
condition.

Neuropathology in AD+P:
a focus on tau
The classical protein pathologies in Alzheimer’s disease
comprise extracellular amyloid-beta (Aβ) plaques and
intracellular neurofibrillary tangles, composed primarily
of hyperphosphorylated tau proteins. As AD+P is a morerapidly progressing disease variant, with evidence of some
localization of disease to the frontal cortex, neuropathological correlation studies are critical in the search for disease
etiology. In general, evidence collected from neuropathological studies supports an association of AD+P with tau,
rather than Aβ pathology.44 This is not entirely surprising,
since in AD distribution of tangle pathology, rather than Aβ
pathology, correlates most closely with disease severity.89
Postmortem studies consistently point to a heavier burden
of tangle pathology in AD+P, with some localization in the
frontal cortex.82,88,90,91
In order to explore tau pathology in AD+P, our group
accessed the ADNI database to look for cerebrospinal fluid
(CSF) evidence of increased tau in AD+P. Previous reports
have linked elevations of CSF total tau with the postmortem
burden of neurofibrillary tangles,92,93 so we approached the
data with the hypothesis that we would find elevations in
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total tau in AD+P relative to AD-P as a reflection of tangle
pathology. Indeed, we found that of the three core CSF AD
biomarkers (Aβ, total tau, phospho-tau), only elevation of
total tau in CSF was statistically significantly associated
with psychosis in AD, driven by a robust association in
females with AD+P.94 In a contemporaneous postmortem
immunohistochemical study of the frontal cortex conducted
by colleagues in the laboratory of Dr Robert Sweet, hyperphosphorylated tau (the main component of neurofibrillary
tangles)95 was overabundant in subjects with AD+P compared with AD-P, strengthening the association of AD+P
with tau.96
Recently, in collaboration with Dr. Sweet, we conducted
a biochemical analysis of phospho-tau epitopes in AD+P
using a high-sensitivity enzyme-linked immunosorbent assay
(ELISA) developed in the laboratory of Dr Peter Davies.97
The ELISAs utilize highly specific monoclonal antibodies
to phospho-tau epitopes that are representative of a range of
tau pathology, from neuritic to pretangle to mature tangles.98
Our experiments were conducted on postmortem tissue
samples from the superior frontal gyri of 71 subjects. As
α-synuclein pathology is known to contribute to a psychotic
phenotype in dementia with Lewy bodies (DLB), we controlled for α-synuclein pathology.99 We observed in women
with AD+P, but not in men with AD+P, a robust association
with tau pathology.100 In females, while levels of nonpathogenic total tau as measured with DA31 antibody ELISA did
not differ between AD+P and AD-P groups, pathogenic
phospho-tau species did differ significantly. AD+P females
had significantly higher levels of phosphorylated tau than
did AD-P females at each epitope interrogated: Ser396/404
(PHF-1), Ser202 (CP13), Thr231 (RZ3), and Ser199/202/
Thr205 (AT8). Males with AD+P, all of whom were not
suffering with clinical DLB prior to death, nonetheless had
an increase in α-synuclein pathology. In males this suggests that α-synuclein may make a unique contribution to
AD+P, while in females tau pathology may be the source
of vulnerability.
Previously conducted neuropathology studies have
not been parsed by sex. There is evidence, however, that
female sex is an independent risk factor for psychosis in
AD.30,46,101,102 There is some support for biological underpinnings of this distinction from imaging studies. An MRI
study in AD+P evidenced reduced frontotemporal cortical
thickness in women, rather than in men, with AD+P.74
Additionally, cerebral perfusion patterns in AD+P have
been shown to be sex-specific.103 The significance of the sex
specificity of the association of AD+P with tau pathology
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is not yet clear, and more research is necessary to confirm
this relationship.

Future directions: a pathologyguided approach
The published research in AD+P points toward an accelerated
cognitive decline, with a particular burden of impairment
affecting performance on frontal tasks. There is strong evidence that degeneration is accelerated in the frontal cortex,
likely mediated by tau pathology, especially in females. This
suggests a model of AD+P in which normative temporo–
parietal deficits of AD are complicated by an accelerated
extension to the frontal cortex. There may be some sex
specificity to this model, and the degree to which the frontal
tauopathy of AD+P is a female problem is not yet clear.
However, the model, in identifying pathogenic proteins and
localization, does enable translational research that may aid
in illuminating in just what regions, and to what degree, tau
pathology may contribute to the psychotic phenotype.
Animal models of psychiatric disease pose a particular
challenge, in that the core of psychiatric illness is experience, something inaccessible in observations of animals that
are language deficient. However, there is a long history of
observing animals under conditions designed to serve as
analogues of precipitants of human behavioral disorders and
of studying physiological changes in these animals; a more
recent history of observing animals with physiological
changes known to be associated with human disease and of
studying behavioral changes. In AD, translational research
relies to a large degree on the advent of transgenic mice
carrying autosomal dominant mutations in human genes that
are known to cause the disease, or to cause pathology associated with the disease. The mice, depending on the identity
of the mutation, produce an abundance of Aβ-driven plaque
or tau-driven neurofibrillary tangle pathology and display
dense cognitive deficits.104 Curiously, to date, these models
have only infrequently been employed to study the behavioral syndromes so common in AD. This raises interesting
questions. Are there outcome measures in mice relevant to
psychosis that could be utilized in such an exploration? If
so, could extant mouse models be employed to elucidate
the neuropathological substrate responsible for AD+P? If
AD+P in humans emerges, in part, secondary to frontal
neurodegeneration driven by tau, could a mouse model
aid in a more-precise localization of the frontal deficits
responsible?
Currently employed paradigms for modeling psychosis
in mice include induction of locomotor hyperactivity and
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disruption of sensorimotor gating, quantified with prepulse
inhibition (PPI) of acoustic startle.105 Locomotor hyperactivity, as a model of psychosis in rodents resulting from
exogenous agents promoting dopamine release, is the conceptual offspring of the hyperdopaminergic hypothesis of
schizophrenia;106 deficits of PPI represent an endophenotype
of psychosis itself that has been associated with schizophrenia
and may have broad relevance in all psychotic states.107 PPI
is defined as the reduction of the intensity of motor startle
in response to a startle stimulus (for example, acoustic)
when the stimulus is preceded by a diminished, nonstartle
stimulus. In a normal state, the startle induced by the startle
stimulus should be significantly gated by the attention paid
to the preceding stimulus. In psychosis, this ability to inhibit
startle is disrupted by a failure of normal gaiting, perhaps
representing a diminished capacity to monitor environmental
stimuli appropriately.108 PPI of acoustic startle as a phenotypic
marker of psychosis may be best described as “the interface
of psychosis and cognition,”105,109 representing a cognitive
failure that potentially influences environmental surveillance
and may promote psychotic misinterpretation. The confluence
of cognitive impairment and environmental misapprehension
implicit in PPI deficiency makes PPI an attractive outcome
measure in investigating potential animal models of AD+P.
In order to develop a preclinical mouse model of AD+P,
we recently selected an AD model manifesting early frontal
tauopathy, the transgenic rTg(tauP301L)4510 mouse,110 and
characterized PPI deficits over time in relationship to tau
pathology.111 We demonstrated that PPI deficits accrued over
time in female rTg(tauP301L)4510 mice, and that these deficits
were driven by the same pathogenic hyperphosphorylated
tau molecules that we had previously observed in the frontal
cortex of human female AD+P subjects.100 This suggests that
the rTg(tauP301L)4510 mouse may be a candidate for preclinical study of AD+P biology and the development of novel
therapeutics. There is more work to be done prior to settling
on any animal model of AD+P. Future studies involving this
model will include expanding the phenotypic characterization of this mouse beyond PPI to include other cognitive
and behavioral markers of psychosis, and exploring the sex
specificity of the observed behavioral characteristics.
The way forward in the treatment of AD+P may transcend traditional psychiatric treatments of psychosis and
may involve the reduction of pathogenic proteins rather
than supporting aberrant neurotransmitter systems that are
the downstream effects of disease pathology. Future treatments may focus on tau pathology, α-synuclein pathology,
or both. Several tau reduction agents are currently in the drug
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development stage for the treatment of AD, and even if they
do not provide a cure for the primary illness, they warrant
exploration in the service of combating a particularly morbid
and common manifestation of the disease.
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